

Fibroblasts as immune regulators in infection, inflammation and cancer

Sarah Davidson¹, Mark Coles¹, Tom Thomas¹, George Kollias^{2,3,4}, Burkhard Ludewig^{5,6}, Shannon Turley⁷, Michael Brenner⁸, Christopher D Buckley^{1,9}

¹ The Kennedy Institute of Rheumatology, University of Oxford, Oxford. UK

² Institute for Fundamental Biomedical Research, Biomedical Sciences Research Center “Alexander Fleming”, Vari, 16672, Greece;

³ Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”, Vari, 16672, Greece;

⁴ Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, 11527, Greece

⁵ Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland. burkhard.ludewig@kssg.ch.

⁶ Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

⁷ Department of Cancer Immunology, 2Oncology Bioinformatics, Genentech, South San Francisco, CA 94080, USA.

⁸ Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA

⁹ Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, B15 2WD, UK.

Correspondence to Christopher Buckley c.d.buckley@bham.ac.uk

Abstract

In chronic infection, inflammation and cancer, the tissue microenvironment controls how local immune cells behave, with tissue-resident fibroblasts emerging as a key cell type in regulating activation or suppression of an immune response. Fibroblasts are heterogeneous cells, encompassing functionally distinct populations, the phenotypes of which vary according to their tissue of origin and type of inciting pathology. Their immunological properties are also diverse, ranging from the maintenance of a potent inflammatory environment in chronic inflammation, to promoting immunosuppression in malignancy and encapsulating and incarcerating infectious agents within tissues. In this review we compare the mechanisms by which fibroblasts control local immune responses, as well as the factors regulating their inflammatory and suppressive profiles, in different tissues and pathological settings. This cross-disease perspective highlights the importance of tissue context, in

determining fibroblast-immune cell interactions, as well as potential therapeutic avenues to exploit this knowledge for the benefit of patients with chronic infection, inflammation and cancer.

1.0 Introduction

Early histological studies in the late 19th century identified fibroblasts by their distinct spindle shaped morphology, a characteristic that delineates them from other structural cells, such as epithelium and endothelium^{1,2}. While fibroblasts were classically thought of as “immune neutral” cells, whose primary function is the construction and remodelling of the extracellular matrix (ECM)³, it is now clear that fibroblasts play a multifaceted role in health and disease. In particular, fibroblasts have emerged as key immune-sentinel cells, activating and modulating immune response upon the detection of pathological stimuli. Like myeloid cells, fibroblasts can detect damage associated molecular patterns (DAMPs) and pathogen associated molecular patterns (PAMPs), activating pro-inflammatory signalling pathways to aid leucocyte recruitment and regulate their activity⁴⁻⁷. . As such, these cells are now acknowledged as a ‘non-classical’ branch of the innate immune system.

Although there are common mechanisms that fibroblasts use to regulate tissue immunity across diseases, others are unique to a single pathology or anatomical location. These properties are shaped by their local tissue environment, as well as specific inciting pathogenic signals. Furthermore, new single cell technologies have revealed that the fibroblast compartment encompasses functionally distinct subpopulations in homeostasis and disease. The identity and function of these populations in health also contribute to their ensuing pathogenic phenotype. Understanding how these elements combine to shape fibroblast function is crucial for the development of therapeutics. Identifying factors regulating fibroblast phenotype in one disease, may be harnessed or repurposed to treat others. For instance, induction of immunosuppressive mechanisms, utilised by fibroblasts in cancer, may aid resolution of chronic immune mediated inflammatory disease. By examining our current understanding of fibroblast-immune interactions- in infection, inflammation and cancer, this review will discuss these themes, aiming to draw parallels and differences across tissue and diseases.

2.0 Fibroblast subsets in health and disease

Despite playing an integral role in tissue homeostasis and pathological processes, our understanding of fibroblast function has been hampered by their intrinsic heterogeneity and a lack of robust markers. While markers such as platelet derived growth factor receptors (PDGFR) α and β , podoplanin (PDPN), Thy1 (CD90) and alpha smooth muscle actin (α SMA) are commonly used to distinguish fibroblasts, many of these markers are neither uniformly nor uniquely expressed by these cells. Indeed, fibroblasts are still identified by the absence of molecules associated with other lineages, such as endothelial (CD31), epithelial (EPCAM) or hematopoietic (CD45) cells. However, revolutions in minimally invasive surgery, including ultrasound mediated biopsy, combined with the advent of technologies such as single cell RNA sequencing (scRNAseq), have transformed our ability to catalogue and assign potential functional properties to distinct fibroblast subsets in human pathology. Furthermore, coordinated international efforts from consortia such as the Human Cell Atlas, ImmGen and the Accelerating Medicines Partnership, have significantly enhanced our understanding of the cellular composition of multiple tissues and biological systems. This approach has begun to unlock the cellular basis of disease, revealing an exciting variety of fibroblast subsets with non-overlapping functional roles. These populations and their unique characteristics will now be reviewed across infection, inflammation and cancer. We will not review the impact of these technologies on fibroblasts responsible for fibrosis as this has been recently covered ⁸.

2.1 Fibroblast heterogeneity in health As early as the 1960s, disparity in functional properties, such as proliferation and secreted factors, was noted between cultured fibroblasts from different tissues ⁹. However, such diversity also exists within a single anatomical location. For example, the transcriptional signatures of the dermal mesenchyme vary across the limbs, diverging from the torso towards the fingers or toes ^{10,11}. Similarly, fibroblasts isolated from different synovial joints display unique expression profiles. In both cases, this feature was retained *in vitro*, suggesting that fibroblasts are imprinted with positional identity. Such imprinting occurs during development and is maintained in the postnatal period by epigenetic regulation of HOX genes ¹². These location specific transcriptional programs are likely to reflect the individual functional requirements of the surrounding tissue. For example, fibroblasts residing in epithelial tissue, such as the gut, possess specialised features to support epithelial cells, in order to maintain barrier integrity

and function¹³. Conversely, in the absence of any epithelium, synovial fibroblasts form a distinct lining layer with resident macrophages which helps maintain synovial health and joint lubrication¹⁴. This concept is supported by a recent scRNAseq study, which demonstrated that fibroblast transcriptional programmes bear more similarities to other structural cells within their organ ecosystem, than fibroblasts from other locations¹⁵.

Furthermore, within a single anatomical location, specialised fibroblast subsets maintain discreet functional sub-compartments. The spatial distribution of fibroblasts in the gut is tailored to the needs of the local tissue environment. For example, SOX6+ POSTN+ fibroblasts, are positioned near the epithelium and display a transcriptional signature indicative of a role in epithelial differentiation and proliferation^{13,16,17}. Moreover, expression of WNT components varies according to spatial location. Specifically, fibroblasts expressing WNT5A/5B reside closer to the villus, whilst those located in the lamina propria express WNT2B¹³. Similarly, in the lung, Axin2+ PDGFR α + fibroblasts reside in the alveolar niche. In organoid cultures, this fibroblast population enhanced self-renewal and differentiation of alveolar stem cells, compared to other subsets. This is mediated by production of FGF7, IL6 and the BMP inhibitor, Grem2¹⁸.

Skin and hepatic fibroblasts also display zonal demarcation. In the dermis, fibroblasts residing in the upper papillary region are spindle shaped, proliferate and help maintain the epidermal structure^{19–21}, while those of the lower reticular dermis are flatter, less proliferative and display increased expression of α SMA¹⁹. Concurrently, NGFR+ hepatic stellate cells (HSCs), a population of liver fibroblastic stromal cells, reside close to the portal vein, whereas those surrounding the central vein express Adamtsl2+²². Interestingly, gene cassettes associated with HSCs from different zones, mirror those of surrounding endothelial cells. This supports the hypothesis that tissue specific properties are imprinted across structural cell types and reflect local organisation.

2.2 Fibroblast heterogeneity in disease. In disease, homeostatic populations expand and gain pathological features that help drive disease progression and persistence. Similar pathological stimuli elicit common functional programmes across organs. For example, fibrosis of the lung and liver induces a fibrotic ‘myofibroblast’ transcriptional program, in discrete local populations. Axin2+ PDGFR α - pulmonary fibroblasts, a population distinct from

the Axin2+ PDGFR α + subset of the alveolar niche ¹⁸, and central vein HSCs, drive fibrotic disease in the lung and liver respectively ²². A similar phenomenon occurs upon viral stimulation, which activates an immune programme in fibroblasts in kidney, lung, skin and liver ¹⁵. However, immune signatures were unique to each organ, indicating pathogenic phenotypes also reflect the surrounding tissue niche.

Furthermore, within individual tissues and disease, distinct fibroblast subsets can mediate different pathogenic responses. In the cancer field, this concept was pioneered by Ohlund *et al*, who uncovered functionally distinct populations of cancer associated fibroblasts (CAFs) ²³. Enriched in the tumour microenvironment, CAFs are fibroblastic cells that aid malignant growth and development via an array of pathogenic properties. These tumour-supporting functions distinguish these cells from their normal counterparts and include promoting angiogenesis, developing a fibrotic matrix, mediating metastasis and modulating immune infiltrates ^{24,25}. In pancreatic adenocarcinoma (PDAC), Ohlund *et al*, identified α SMA+ myofibroblasts juxtaposed with a discrete IL6 expressing CAFs, termed myCAFs and iCAFs respectively. A unique *in vitro* system further revealed myCAFs display a matrix-remodelling gene expression profile, while iCAFs express cytokines and chemokines indicative of immune-cross talk. ²³. Following this study, the landscape of the mesenchymal compartment has been extensively profiled across a number of murine tumour models and human malignancies. These include breast, pancreatic, melanoma, lung, glioblastoma and head and neck ^{26–32}. One of the first studies investigating the functional properties of distinct fibroblast populations in cancer was performed by Costa *et al*, in human breast tumours ²⁷. Using flow cytometry, the authors identified four populations based on their expression of CD29, FSP1, FAP, α SMA, PDGFR β and Caveolin1. Similar to Ohlund *et al*.’s iCAF population, one of these subsets also regulates the immune microenvironment, inducing regulatory T cell differentiation. In combination with more recent scRNAseq studies, it is now evident that the pathogenic properties of fibroblasts, previously assumed to be ubiquitous, such as ECM remodelling, antigen-presentation and vascular support, pertain to specific subpopulations.

Furthermore, distinct fibroblast populations can also dictate the efficacy of cancer therapies. For example, in breast and lung cancer, a discrete IL6 producing population promotes resistance to chemotherapy, by enhancing cancer stem-cell survival ³³. Similarly, a

subset of CAFs in breast cancer, reduces expression of the oestrogen receptor on malignant cells, diminishing their sensitivity to tamoxifen ³⁴. Moreover, further investigation of the immune modulating population identified by Costa *et al*, uncovered additional functional subsets which resemble both the iCAF and myCAF phenotypes. Interestingly, iCAF clusters were associated with CD8+ T cell infiltration and a positive response to immunotherapy, whereas myCAFs were associated with resistance to therapy ³⁵. This association may be mediated by the ability of myCAFs to promote Treg differentiation and upregulation of immune-checkpoint molecules.

Discrete pathogenic populations are also present in chronic inflammatory disease. Indeed, the functional properties of fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) are determined by their anatomical location in the joint ³⁶. The synovial membrane can be divided into two distinct mesenchymal structures. This includes an epithelial like membrane, known as the lining layer (LL), which is composed of fibroblasts and macrophages, as well as the underlying sublining (SL), where endothelial cells are located ^{36,37}. While both compartments are disrupted in disease, the SL alone becomes infiltrated with leucocytes and greatly expands ³⁸. LL and SL fibroblasts can be identified by distinct marker repertoires; while Prg4, Cd55 and Clic5 mark the LL population, Thy1 and CD34 define various subsets within the SL ^{36,39}. Furthermore, recent finding in both mice and humans, reveal that FLS in the LL display tissue destructive transcriptional signatures and are likely responsible for bone and cartilage damage. In contrast, SL fibroblasts display a pro-inflammatory signature and are characterised by expression of Thy1, PDPN and FAP ^{36,39}. These functional programs were validated by adoptive transfer of Thy1- and Thy1+ populations in murine models. Here, Thy1+ populations promoted leukocyte accumulation and inflammation, while Thy1- fibroblasts promoted damage and bone erosion ³⁶.

Analogous to RA, pathogenic subsets have also been uncovered in ulcerative colitis (UC). However, owing to the large differences in the number of cells sequenced, their characterisation is hampered by considerable variability. Nevertheless, across these datasets, the spatially distinct populations identified in normal gut tissue, are also present in disease ^{13,16,17}. Upon exposure to inflammatory stimuli, fibroblasts in the lamina propria adopt an activated THY1+ PDPN+ FAP+ inflammatory phenotype, resembling SL fibroblasts in RA, which expands in UC ¹³. Furthermore, owing to a high number of sequenced cells,

Smilie et al. were able to distinguish this THY1+ PDPN+ FAP+ population from a distinct WNT2B+ RSPO3+ CCL19+ CCL21+ population¹³. The latter is thought to interact with LRG5 expressing intestinal stem cells and is associated with poor prognosis in colorectal cancer.

2.3 Common themes across anatomical sites and diseases. Although a diverse array of functional subsets have been described, a re-occurring theme across both disease and tissue is the identification of two main phenotypes: -'immune-interacting' and 'tissue remodelling'. Thus, the iCAF and myCAF populations defined by Ohlund *et al*, may represent a shared paradigm²³. Here, inflammatory fibroblasts express cytokine and chemokines, indicating an important role in attracting and maintaining immune cells. This may aid persistent inflammation in RA, inflammatory bowel disease (IBD) and cancer. However, a separate subset produces and activates connective tissue components and remodelling enzymes. While these properties are critical for tissue repair, dysregulation in disease leads to pathological matrix remodelling in cancer and fibrosis. The identity of this remodelling population is dependent upon the local tissue ecosystem. For example, fibrosis is not a common feature in RA, thus, remodelling in this context refers to the interactions between LL fibroblasts and the surrounding cartilage and bone. Like fibrosis and cancer, aberrant remodelling driven by this population, causes significant tissue damage. **(Figure 1)**

Interestingly, across disease, these populations are induced and maintained by similar signalling networks. For example, NFκB and the JAK/STAT pathways are key regulators of the immune-interacting phenotype⁴⁰⁻⁴⁵. Activation of these pathways is induced by a variety of signals, including sensing of pathology and damage by PAMPs, such as Toll-like receptors, as well as inflammatory cytokines such as TNF and IL1B^{4-6,46-50}. Indeed, the TNF^{ΔARE} mouse model, in which TNF overexpression leads to RA- and Crohn's-like-pathology, showed that synovial and intestinal fibroblasts are necessary and sufficient targets of TNF, orchestrating both pathologies⁵¹. Furthermore, in both cancer and RA, initial stimulation by inflammatory factors, is sustained by an autocrine positive feedback loop. Here, activation of the NFκB in fibroblasts, leads to production of LIF. This, in turn, activates the STAT pathway, augmenting their inflammatory signalling network^{40,52}. Fibroblasts in IBD also lie at the centre of a positive feedback loop, engaging in paracrine interactions with adjacent leukocytes. Here commensal bacteria induce production of TNFα and IL1B in innate immune cells, such as monocytes, which elicits a pro-inflammatory phenotype in local fibroblasts and leads to

further immune recruitment ⁵³. Similarly, the JAK/STAT upstream activator oncostatin M, also promotes expression of pro-inflammatory factors in peripheral tissue fibroblasts and is associated with anti-TNF resistance in IBD ^{54,55}.

While pro-inflammatory cytokines appear to regulate the fibroblast immune-interacting phenotype, TGF β production and matrix stiffness are integral for the induction of myofibroblast differentiation ^{56,57}. Specifically, in cancer, the development of a fibrotic matrix also establishes a positive feedback loop to maintain the myCAF phenotype. Here, increased matrix rigidity activates YAP/TAZ signalling, enhancing fibroblast contractility, which further stiffens the surrounding ECM ⁵⁶. In addition, in fibrosis, the wnt pathway has also been shown to promote myofibroblast activation and expansion ¹⁸. However, factors driving the acquisition of tissue remodelling and damage in RA remain elusive.

The stromal niche varies from organ to organ, depending on the type of structural cells present, and plays an important role in the activation of both immune-interacting and remodelling fibroblasts. This was recently demonstrated by Wei et al. who elegantly showed that Notch ligands JAG1 and DLL4, expressed on the surface of endothelial cells, engage Notch3 on immune-interacting fibroblasts, inducing their expansion in disease ³⁷. Conversely, an almost identical interaction between endothelial cells and hepatic stellate cells in liver fibrosis, induced a pathogenic remodelling phenotype ⁵⁸. This highlights the importance of disease and tissue context in determining the outcome of pathogenic signalling networks. **(Figure 1)**

Furthermore, such intrinsic differences in tissue and disease states determine the presence and proportion of remodelling and immune-interacting fibroblasts. Although these subsets exist in tandem across many types of cancer and arthritis, this dichotomy may not be universal. For example, remodelling fibroblasts are the dominant population in liver and lung fibrosis, while immune-interacting subsets appear to monopolise UC. ^{13,17,18,22,58}. In addition, inflammatory fibroblasts described by Kinchen et al also express the matrix cross-linking enzyme LOX, which suggests that these two phenotypes may not be mutually exclusive ¹⁷. However, this subset does not express the full complement of genes associated with matrix remodelling populations in fibrosis and cancer. Thus, a true myCAF counterpart,

in UC, likely remains elusive. Interestingly, Biffi et al. demonstrate plasticity between the iCAF and myCAF states, which are regulated by the surrounding soluble milieu ⁴⁰. In this system, TGF β disrupts NF- κ B signalling, cause fibroblasts to transition from iCAFs to myCAFs. Similarly, activation of the transcription factor PU.1 promotes matrix remodelling properties in fibrosis, even in the presence of TNF ⁵⁹. This plasticity may explain the expression of both inflammatory and remodelling genes in a single population. However, it also raises the fundamental question of whether immune-interacting and remodelling populations, across tissue and disease, exist in a similar polarised system or develop from distinct pre-existing populations due to differential cues. **(Figure 2).**

3.0 Fibroblasts as immune regulators

A successful inflammatory reaction relies on a careful balance of immune recruitment, activation and resolution. Indeed, perturbation of this equilibrium leads to aberrant immunity, which can exacerbate disease pathology. The conservation of immune-interacting fibroblasts, across anatomical location and disease, highlights their pivotal role in local tissue immunity. Their immunological properties range from recruitment and activation of immune cells, to immunosuppression and removal of inflammatory infiltrates. This reflects inter-tissue heterogeneity, which plays an important role in determining the local immune response. Here, expression of particular surface molecules and leukocyte recruitment factors, enable fibroblasts to communicate their anatomical location to circulating immune cells. Known as the 'stromal address code', unique combinations of signalling molecules dictate the identity of recruited leukocyte populations and the behaviour appropriate for the surrounding tissue ⁶⁰. For example, naïve cells are recruited to secondary lymphoid organs, whereas memory cells are recruited to peripheral tissues ⁶⁰. By governing recruitment, activation and removal of immune cells, fibroblasts act as custodians of immunological balance, tipping the scales from controlled immunity to persistent and un-resolving inflammation, or to an immunosuppressive environment. In the following sections we will explore how the fibroblast command the immune response in infection, inflammation, and cancer.

3.1 Immune regulation in lymphoid tissue. While the importance of fibroblast-immune interactions in peripheral tissues is rapidly emerging, their role in primary and secondary lymphoid organs (SLOs) has long been appreciated. Lymphoid tissue, such as bone marrow, lymph nodes, Peyer's patches and splenic white pulp, control the appropriate differentiation and release of circulating leukocytes, as well as enable innate and adaptive cells to converge and converse⁶¹. This is reflected in the stromal address code of local fibroblasts which, through a network of soluble factors and adhesion molecules, coordinate the position, preservation and phenotype of immune cells within these tissues. For example, bone marrow fibroblasts primarily function to constrain immature cells, until differentiation occurs and release into the blood is appropriate. This is mediated by the secretion of CXCL12 and expression of the adhesion molecule VCAM,1 which bind CXCR4 and integrin $\alpha 4 \beta 1$ respectively. However, bone marrow fibroblasts also promote B-cell maturation, a process mediated by a separate, IL7 producing population^{62,63}. Conversely, SLOs are instrumental for the activation of acquired immunity⁶⁴. Similar to peripheral organs, the functional organization of classical SLOs is underpinned by highly specialized fibroblastic stromal cells, which are usually referred to as fibroblastic reticular cells (FRCs). Recent scRNAseq analyses have categorized and elaborated phenotypical differences of FRC subsets⁶⁵⁻⁶⁸. Broadly, the particular anatomical location and the immune cells they interact with, determines the FRC subset identity. For example, T cell zone reticular cells (TRCs), are located in the paracortex where they orchestrate T-cell priming by antigen-bearing dendritic cells (DCs). This involves recruitment, homing and maintenance of naïve T cells, via secretion of chemoattractants CCL19, CCL21 and CXCL12, and the lymphocyte growth factor IL-7⁶⁹⁻⁷¹. B cell-interacting reticular cells (BRCs, including the follicular dendritic cells (FDCs) of the germinal centre), produce CXCL13, to recruit and maintain a pool of naïve B cells^{72,73}. Conversely, marginal reticular cells (MRCs) are situated between the subcapsular sinus and B cell follicles. Here, they regulate local macrophages and lymphatic endothelial cells, as well as acting as a source of FDCs during the formation of germinal centres^{74,75}. Other FRC populations include medullary reticular cells (MedRCs) and perivascular reticular cells (PRCs)⁶⁴.

Importantly, FRCs also employ several mechanisms to promote tolerance to self-antigens and regulate immune responses against commensal bacteria. This involves activating

regulatory T cells, as well as coordinating a suppressive soluble environment, through the enzymatic activity of indoleamine 2,3 dioxygenase (IDO) and cyclooxygenase-2 (COX2) ⁷⁶. Moreover, FRCs can directly present antigen to T and B cells, which both activates adaptive immune responses, as well as deletes or induces dysfunction of self-reactive lymphocytes ^{77,78}. Thus, the stromal address codes of fibroblasts in lymphoid tissue is centred around regulation of innate lymphoid cells, myeloid cells, as well as recruitment, activation and retention of lymphocytes. However, it also includes mechanisms of immune suppression to maintain homeostasis.

3.2 Coordinated immune responses to infectious agents. Immune surveillance is enforced by the recognition of pathogens and the well-orchestrated activation of innate and adaptive immune responses in SLOs. Like peripheral tissues, FRC subset identity in homeostasis, is preserved in the inflamed state ^{66,68}. However, viral infection reprograms FRC properties to direct innate and adaptive immune cell migration and differentiation. This includes FRC-generated chemokine gradients to localize proliferating B cells to the T-B border, thereby causing stretching of the BRC network to create the germinal centre dark zone ⁷⁹. Moreover, FRCs in lymph nodes draining the site of viral infection profoundly change the expression patterns of genes involved in antigen presentation, extracellular matrix, chemokine and cytokine signalling ⁸⁰. Again, reflecting their peripheral counterparts, FRC properties are regulated by distinct cues from interacting immune cell partners. For example, T helper cells-derived IL-17 locally activates TRC and may metabolically support fibroblast proliferation and survival ⁸¹.

Crucially, after pathogenic clearance, FRCs aid the return to lymph node homeostasis. This is mediated by promoting lymphangiogenesis, via transporting VEGF to lymphatic vessels, which facilitates removal of lymphocytes ⁸². In addition, during an immune response, LNs swell to accommodate T cell expansion. This is enabled by FRCs, which reduce contractile tension in the reticular network. Upon resolution, FRCs contract this network and become quiescent, allowing lymph node shrinkage ⁷⁶. Indeed, acute transcriptional reprogramming of lymph node FRCs is transient ⁶⁶, as gene expression profiles following removal of the viral infection are similar to those recorded in naive mice ⁶⁸. Thus, the degree of inflammation-induced transcriptional remodelling reflects the dynamic nature of FRC-immune cell

interaction, that varies temporally, and is indicative of the adaption of the particular immune environment to different pathogens.

Besides the role of FRCs in the functional organization of SLOs during infection, tissue-resident fibroblasts also exert physiological functions in direct response to microbial signals. This includes activation of Cox2/PGE2⁸³, NF- κ B, MAPKs and the inflammasome⁸⁴. Moreover, fibroblasts directly recognise microbes via TLRs and activation of MyD88, instigating tumour regulatory responses⁴⁷. In intestinal chronic inflammation and fibrosis, specific microbiota may be required for TL1A-mediated fibroblast activation and transformation to myofibroblasts⁸⁵. Additional evidence is now beginning to emerge that microbial metabolites are also directly sensed by fibroblasts and modulate inflammation and fibrosis in mice⁸⁶.

3.3 Skewing immunological balance towards persistent inflammation. Chronic inflammation is characterised by persistent leukocyte retention, in the absence of resolution and repair. During resolution, immune populations are removed from peripheral tissues by reducing survival cues, upregulating apoptotic signals and increasing lymphatic drainage. Disruption of these processes, as well irregular chemokine gradients, results in the capture and accumulation of inflammatory cells. Local fibroblasts drive this disorder by altering their stromal address code to reflect FRCs in lymphoid tissue, leading to recruitment and retention of leukocytes.

This begins with the recruitment of myeloid cells, highlighted in a recent study by Martin et al. Here, they discerned a population of activated fibroblasts in Crohn's disease, expressing CCR2 ligands; CCL2 and CCL7⁸⁷. Ligand-receptor analysis confirmed an interaction between these fibroblasts and a population of monocytes expressing S100A8, S100A9 and S100A4. Furthermore, scRNAseq from paired PBMCs indicated this population migrates from peripheral blood into tissue. Concurrent expression of ACKR1 on activated endothelial cells was suggestive of interplay between fibroblasts and endothelium, which enables transcytosis of inflammatory monocytes.

Although myeloid infiltration is a common feature of inflammatory disorders, it is the switch from innate to adaptive immunity that demarcates the development of persistent

inflammation, correlating with worse outcomes and poor treatment response^{88,89}. Fibroblasts aid this transition by recruiting and maintaining lymphocyte populations in peripheral tissues. For example, in UC, the WNT2B+ RSPO3+ C3+ subset expresses lymphocyte recruitment factor, CCL19¹³. Similarly, FLS in RA upregulate CXCR4 on the surface of T cells, to attract and retain lymphocytes within the tissue⁹⁰. Once locally confined, FLS promote lymphocyte survival, proliferation and activation by production of type 1 interferons, IL-6, B cell activating factor (BAFF) and A Proliferation Inducing Ligand (APRIL), as well as direct antigen presentation^{5,91–94}.

Crucially, whilst homeostasis in lymphoid tissues is restored after pathogenic infection, fibroblasts in persistent inflammation sustain lymphocyte retention. This may reflect the inability of inflammatory fibroblasts to return to a homeostatic state. Indeed, these cells are resistant to apoptosis, and retain pathological features in the absence of disease. For example, when implanted into healthy tissue of severe combined immunodeficient mice, cultured RA fibroblasts, but not osteoarthritis fibroblasts, recapitulate aspects of disease such as local cartilage invasion⁹⁵. In addition, FLS isolated from RA, showed an increased propensity for activation of inflammatory pathways, upon re-stimulation (reviewed⁹⁶). Akin to ‘positional identity’, this may be mediated by epigenetic modifications, such as DNA methylation. Indeed, methylation patterns are altered at early stages of inflammation, and continue to change as the disease advances^{97–99}. The stability of these changes *in vitro*, suggests that inflammatory disease imprints a pathological phenotype onto local fibroblasts, preventing reversion to a homeostatic state¹⁰⁰. **(Figure 3)**

3.4 Organisers of tertiary lymphoid structures Chronic inflammation necessitates the presence of an immune outpost in peripheral tissue to recruit and sustain lymphocytes. Thus, in addition to attracting and restraining leukocyte populations, fibroblasts also acquire functional and phenotypic properties to facilitate the formation of tertiary lymphoid structures (TLS), which perpetuate the immune response¹⁰¹. These ectopic sites of lymphoid neogenesis, consist of an organised structure of lymphocytes (B cell and naïve CCR7+ L-selectin+ T cells), myeloid cells (DAMP3+ DCs) and stromal cells.

Ectopic lymphoid neogenesis resembles development of SLOs, which are dependent on the interplay between mesenchymal lymphoid tissue organiser (LTo) cells and haemopoietic lymphoid tissue inducers (LTi) cells, via the LT β R signalling pathway¹⁰². In the context of persistent inflammation, it is likely that priming of a stromal cell occurs through chronic exposure to pro-inflammatory cytokines such as members of the TNF family, IL-4-7, IL-13, IL-15, IL-17, IL-22, IL-23 and IL-27 with varying degrees of dependence on ROR γ ^{70,103–108}. The source of these factors, and thereby the counterpart of the LTi in ectopic lymphoid neogenesis, are innate immune cells, such as myeloid cells and granulocytes^{101,109,110}. Following priming, subsequent organisation of TLS by the LTo is partially dependent on LTBR and TNF signalling and activation of the NF- κ B cascade^{67,111–113}. LT $\alpha\beta$ /LT β R signalling and expression of chemokines, establishes organised zones of B and T cells. Vascular regions in the T cell zones differentiate into structures resembling high endothelial venules (HEV). Upregulation of peripheral node addressins in these regions allows recruitment of CCR7+ L-selectin+ naïve T cells. Across anatomical locations, TLS preferentially form near vascular structures and the corresponding LTo cells include a variety of stromal cells, such as α SMA+ fibroblastic cells, myofibroblasts and pericytes^{114,115}. Thus, both the priming of the LTo stromal cell and the corresponding spatial distribution of the TLS is tailored to the surrounding proinflammatory milieu and tissue type.

The effector function and clinical implications of TLS in disease are the subject of much debate. Although some studies postulate that CXCL13 and ectopic lymphoid neogenesis, are drivers of inflammation in rheumatoid arthritis, correlating with poor clinical outcomes, this is disputed by others^{116–121}. In IBD, CCL19+ CCL21+ stromal cells have recently been discerned in single cell analysis^{13,17,87}, potentially representing LTo-like cells. However, it is still too early to conclude whether TLS are simply associated with IBD, as opposed to a key driver of inflammation. On the other hand, in Sjogren's syndrome (SS), there is a clinical association with poor prognosis. Here, TLS promote autoantibody production, potentially driving expansion of malignant autoreactive B cell clones^{108,122,123}.

Conversely, in cancer, TLS are associated with improved prognosis (reviewed by Fridman¹²⁴) and have recently been demonstrated to heighten the efficacy of immune checkpoint inhibitors¹²⁵. This dichotomy reflects key differences between the immune microenvironment of chronic inflammatory disorders and malignancy. While the former is

characterised by recruitment and retention of pro-inflammatory immune populations, tumours cultivate an immunosuppressive niche to enable their growth¹²⁶. Although immune cells can detect neo-antigens produced by genetically unstable tumours^{127,128}, the malignant microenvironment dampens their activity. This is mediated by recruiting regulatory cells, inducing suppressive phenotypes or actively excluding leukocytes (reviewed¹²⁹). Restoration of effector functions by immunotherapies has led to immune-mediated destruction of tumours, in melanoma, lung, renal and head and neck cancer^{130–133}, illustrating the importance of a robust immune response in determining malignant progression. Similar to chronic inflammatory disorders, TLS in cancer are composed of dendritic cells, T and B lymphocytes, as well as HEVs^{134–136}. It is thought that TLS promote anti-tumour immunity by facilitating DC antigen presentation, enhancing cytotoxicity and promoting T-cell mediated B cell differentiation^{137–139}. In turn, plasma B-cells produce antibodies against tumour antigens and are thought to directly present antigen to CD8 T-cells, further augmenting their activity^{139–142}. While robust T-cell responses are associated with TLS formation^{136,137}, it remains unclear whether TLS truly heighten anti-tumour immunity or are merely an indication of a functional immune response (**Figure 4**).

3.5 Promoting immunological tolerance in cancer. While little is known about the role of stromal cells in TLS formation in cancer, CAFs are intimately involved in immune recruitment and regulation in the malignant microenvironment. Thus, their stromal address code may determine the potency of the anti-tumour immune response, dictating disease outcome. Similar to FLS and gut fibroblasts, CAFs also acquire properties associated with the lymphoid mesenchyme. A key component of the iCAF inflammatory secretome, in PDAC and melanoma, are factors that act to recruit and regulate myeloid cells^{28,29}. Indeed, across malignancies, CAFs attract and maintain tumour associated macrophages (TAMs) via secretion of CCL2, CCL5, CXCL1, CXCL12, IL-6 and Chitinase-3 like 1 (Chi3L1)^{45,143–148}.

However, again, it is the presence of lymphocytes that determines prognosis^{148–150}. In contrast to fibroblasts in inflammatory disease, CAFs have been shown to exclude lymphocytes and mimic the suppressive properties of FRCs, promoting tumour immune evasion. While CAFs also adopt the CXCL12-CXCR4 axis to restrain T cells, instead of amassing lymphocytes in the tissue, the peripheral location of CAFs in PDAC, prevents T cell

infiltration¹⁵¹. Tumour fibroblasts also suppress T cell activity via production of soluble cues, such as PGE2, and immune checkpoint ligands PDL1 and PDL2^{152,153}. In addition, while CAFs are able to present antigens, this interaction is utilised to suppress and delete CD8 T-cells. Akin to the mechanisms of self-tolerance in the LN, FasL and PDL2 on the surface of CAFs, repress T-cells in an antigen dependent interaction¹⁵³. CAFs further promote a tolerogenic environment by recruiting and restraining regulatory T cells, via CXCL12 and adhesion molecules OX40L and JAM2, as well polarising myeloid cells^{27,145}. This includes inducing immunosuppressive phenotypes in TAMs, by secreting CXCL12 and Chi3L (Cohen et al., 2017; Comito et al., 2014)^{144,145}, and reducing the ability of DCs to present antigens and activate T cell responses. This is mediated by production of the metabolite tryptophan metabolite kynurenine by tryptophan-2,3 dioxygenase, which downregulates costimulatory molecules on DCs, as well as promoting expression of regulatory cytokines TGF β and IL10¹⁵⁴. Similar to inflammatory diseases, maintenance of this unique immune microenvironment, may be driven by epigenetic imprinting of tumour fibroblasts. Indeed, CAFs display discrete DNA methylation patterns, which maintain their pathological properties^{155–157}. Thus, it is possible that while fibroblast epigenetic remodelling enables persistent inflammation in chronic inflammatory disorders, in cancer, it may promote continuous tumour immune privilege.

4. Importance of location and disease in fibroblast function

The relationship between tissue specificity and pathological cues in sculpting fibroblast phenotype and heterogeneity in disease, is a source of much debate. On one hand, tissue-specific transcriptional programs shape the identity of local functional subsets. This influences the composition of populations in pathology and their associated functions, which may explain the predisposition of anatomical sites to certain types of diseases. For example, viral tropism (skin, gut, brain), chronic inflammatory diseases (gut, joints, skin) and metastatic spread to certain tissues (bone marrow, lung, lymph node). Tissue imprinted functional properties are particularly pertinent in the tumour microenvironment, owing to the multiple origins from which CAFs may be derived. As well as transformation of tissue resident fibroblasts by malignant cues, CAFs also originate from pericytes, tumour cells undergoing epithelial-mesenchymal transition, endothelial cells undergoing endothelial-mesenchymal transition and bone marrow stromal cells that migrate into peripheral tissues

from circulation ^{158–163}. Interestingly, a recent study in breast cancer highlighted different functional properties associated with recruited bone marrow fibroblasts, compared to tissue residents CAFs ¹⁶⁴. This indicates that fibroblasts from different tissues retain functional programmes even when exposed to a new local environments.

On the other hand, the relative composition of fibroblasts can change depending on the pathological insult. For example, in the synovium, inflammatory populations are enriched in leukocyte-rich RA, while populations involved in tissue damage are more prevalent in osteoarthritis ³⁹. Similarly, in breast cancer, a distinct immune-regulatory CAF population is enriched in triple negative, compared to luminal tumours ²⁷. This indicates that while certain features are imprinted, some plasticity is retained. Given that they are embedded in a network of immune, epithelial and endothelial populations, fibroblasts can adapt their properties and address codes to complex paracrine cues from surrounding cells.

This highlights the importance of bioinformatic tools such as CellPhoneDB and NicheNet to interrogate single cell sequencing data ^{165,166}. These systems produce a ranked list of putative interactions between cell types, creating a powerful system to investigate cell-cell communication, in the heterogeneous environment of disease. Understanding these interactions may enable therapeutic modulation of fibroblast immune-regulatory properties, to promote immune tolerance in chronic inflammation or cytotoxicity in cancer (Table2). However, it is important to bear in mind that bioinformatic insight should be supported by functional evidence and assigning function to groups of cells based on the transcriptome might not be biologically accurate.

5.0 Therapeutic avenues for targeting fibroblasts in disease

An in-depth understanding of the markers that define fibroblast heterogeneity as well as the surrounding tissue ecosystem, is required if fibroblast biology is to transition from bench to bedside (Figure 5). The difficulties associated with selective fibroblast depletion, through targeting FAP in oncology, illustrates the challenges involved. As FAP is highly expressed on CAFs in a variety of cancers, concerted efforts have been made to deplete FAP+ CAFs using immunotoxin, antibodies, DNA vaccines and chimeric antigen receptor (CAR) T cells ^{167–171}. These strategies were successful in attenuating tumour growth, yet owing to expression of FAP in normal tissues, also resulted in cachexia and anaemia ^{167,169,171,172}. Furthermore, the

dangers of using single marker approaches to target CAFs without prior knowledge of their functional properties, are illustrated by their depletion in PDAC. Here, depletion of FAP+ CAFs promoted T cell infiltration and synergises with immune checkpoint therapies ¹⁵¹. However, elimination of α SMA+ CAFs promoted undifferentiated tumour growth and reduced survival ¹⁷³.

An alternative strategy is to target downstream functions of specific fibroblast subsets. For example, clinical trials are ongoing for the TGF β inhibitor galunisertib, which aims to reduce CAF matrix production and increase anti-tumour immunity ^{174,175}. In a similar vein, it is hoped that the CXCR4 inhibitor, AMD3100, will prevent CXCL12 mediated T-cell exclusion and enable lymphocyte infiltration into the tumour ^{176,177}. Another approach involves targeting the inductive programmes that initiate pathological phenotypes in fibroblasts. In cancer, inhibitors of the FGFR and the vitamin D receptor, aim to broadly reduce CAF activation ^{178,179}. Interestingly, this was also achieved by administration of tyrosine kinase inhibitors, which were initially designed to inhibit tumour cell signalling. It is thought these modulate fibroblast activity via interactions with PDGFRs and FGFR and has led to the repurposing of nintedanib for treatment of pulmonary fibrosis ^{180–182}.

However, as fibroblasts are composed of functionally distinct populations, it is critical to understand the programs that regulate each population, to enable specific targeting. Furthermore, this strategy raises the possibility of harnessing inductive programs in one disease, to treat another. For example, inhibiting NOTCH3 signalling between endothelial cells and FLS, reduced expansion and reversed the pro-inflammatory phenotype of THY-1+ fibroblasts in RA (Wei et al., 2020). Thus, targeting the NOTCH3 receptor may represent a therapeutic avenue for other chronic inflammatory diseases. Indeed, NOTCH3 is expressed on the THY1+ fibroblasts in the gut lamina propria. Other examples include targeting the NF- κ B amplification loop and interactions with inflammatory macrophages.

Additionally, inductive programs that promote immunosuppressive phenotypes in tumour fibroblasts, may also be used to resolve chronic inflammatory disease. However, while we are starting to understand drivers of the iCAF phenotype, upstream factors inducing their suppressive properties are yet to be elucidated. On the other hand, scRNAseq has begun to

shed light on the mechanisms promoting remission of chronic inflammatory disorders. Conditions such as RA and IBD, can be cyclic in nature, in which patients experience periods of remission. In RA, Alivernini et al elegantly demonstrate that fibroblasts in remission adopt tolerogenic and resolving phenotypes, as evidenced by expression of IGFBP5/6 and AXL¹⁸³. This is induced by a unique MerTK+ macrophage population, that is enriched during the remission phase. However, this interaction is bidirectional, as production of GAS6 by THY1^{pos}CXCL14 fibroblasts, activates MerTK signalling in myeloid cells. siRNA abrogation of GAS6, in FLS-macrophage co-cultures, reduces the resolving phenotype of this macrophage subset, reciprocally causing THY1+CXCL14+ fibroblasts to acquire a pro-inflammatory phenotype. This highlights how changes in the local tissue composition, during different disease states, impacts fibroblast properties. Activating these signalling networks in persistent disease may polarise fibroblasts towards a tolerogenic phenotype, ameliorating inflammation.

However, it is important to understand tissue context before modifying cellular signalling or repurposing drugs. This is highlighted by unsuccessful attempts to adopt cytokine blockade strategies from inflammatory rheumatological conditions into treatment of CD. IL-6 trans-signalling was postulated as a key mechanism in mediating resistance of T cells to apoptosis in CD¹⁸⁴. However, clinical trials investigating IL-6 blockade noted gastrointestinal abscess and perforations in treated patients¹⁸⁵. This is a known side-effect in patients undergoing anti-IL-6 therapy for rheumatological indications¹⁸⁶. Similarly, animal models and genome wide association studies implicated a role for IL-17 in the pathogenesis of CD¹⁸⁷⁻¹⁸⁹. However, not only were inhibitors of the IL-17 pathway ineffective, but they also resulted in worsening colitis^{190,191}. In both IL-6 and IL-17 blockade strategies, the pleiotropic nature of the cytokines involved and their impact on the intestinal epithelium was not fully understood. These two cytokines are integral for intestinal tight junctions, through regulation of claudin-2 and occludin respectively^{192,193}. As such, whilst negating these pathways were efficacious in rheumatological conditions, blocking them in context of active mucosal inflammation led to adverse events.

6.0 Conclusions and future developments

Fibroblasts are complex multifaceted tissue-resident sentinel cells, shaped by the needs of the surrounding tissue, via epigenetic imprinting during embryogenesis. Upon challenge with a range of different tissue insults, they help to initiate, govern and moderate subsequent immune responses. This includes interaction with granulocytes, myeloid cells, as well as modulating lymphocyte recruitment and retention. If necessitated, particularly in the case of infection, this leads to the creation of immune outposts, in the form of tertiary lymphoid structures. However, in diseases such as chronic inflammatory disorders and cancer, inappropriate fibroblast activation facilitates disease persistence, by induction of pro-inflammatory and immunosuppressive properties respectively. Knowledge of these pathological properties may be harnessed to restore homeostasis across disease. For example, exploiting tolerogenic features may aid resolution of autoimmune disorders, while stimulating an inflammatory response may promote anti-tumour immunity. Thus, unravelling the composition and function of fibroblasts in homeostasis and disease will unlock their therapeutic potential in tissue repair, whilst minimising the risk of adverse effects associated with directly targeting immune cells.

References

1. Duvall, M. *Atlas d'Embryologie* . (Masson, 1879).
2. Virchow, R. *Die Cellularpathologie in Ihrer Begründung auf Physiologische und Pathologische Gewebelehre*. (Hirschwald, A, 1858).
3. Tarin, D. & Croft, C. Ultrastructural features of wound healing in mouse skin. *Journal of anatomy* **105**, 189–190 (1969).
4. Beat Michel, K. A. *et al.* Chemokine Secretion of Rheumatoid Arthritis Synovial Fibroblasts Stimulated by Toll-Like Receptor 2 Ligands. *J Immunol* **172**, 1256–1265 (2004).
5. Bombardieri, M. *et al.* A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. *Annals of the Rheumatic Diseases* **70**, 1857–1865 (2011).
6. Brentano, F., Schorr, O., Gay, R. E., Gay, S. & Kyburz, D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. *Arthritis and Rheumatism* **52**, 2656–2665 (2005).
7. Seki, E. & Brenner, D. A. Toll-like receptors and adaptor molecules in liver disease: Update. *Hepatology* **48**, 322–335 (2008).

8. Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. *Nature* vol. 587 555–566 (2020).
9. CASTOR, C. W., PRINCE, R. K. & DORSTEWITZ, E. L. Characteristics of human “fibroblasts” cultivated in vitro from different anatomical sites. *Laboratory investigation; a journal of technical methods and pathology* **11**, 703–713 (1962).
10. Chang, H. Y. *et al.* Diversity, topographic differentiation, and positional memory in human fibroblasts. *Proceedings of the National Academy of Sciences of the United States of America* **99**, 12877–12882 (2002).
11. Rinn, J. L., Bondre, C., Gladstone, H. B., Brown, P. O. & Chang, H. Y. Anatomic demarcation by positional variation in fibroblast gene expression programs. *PLoS genetics* **2**, e119 (2006).
12. Frank-Bertoncelj, M. *et al.* Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions. *Nature Communications* **8**, (2017).
13. Smillie, C. S. *et al.* Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. *Cell* **178**, 714–730.e22 (2019).
14. Culemann, S. *et al.* Locally renewing resident synovial macrophages provide a protective barrier for the joint. *Nature* vol. 572 670–675 (2019).
15. Krausgruber, T. *et al.* Structural cells are key regulators of organ-specific immune responses. *Nature* **583**, 296–302 (2020).
16. Huang, Y. *et al.* Single cell transcriptomic analysis of human mesenchymal stem cells reveals limited heterogeneity. *Cell Death and Disease* **10**, 1–12 (2019).
17. Kinchen, J. *et al.* Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease. *Cell* **175**, 372–386.e17 (2018).
18. Zepp, J. A. *et al.* Distinct Mesenchymal Lineages and Niches Promote Epithelial Self-Renewal and Myofibrogenesis in the Lung. *Cell* **170**, 1134–1148.e10 (2017).
19. Janson, D. G., Saintigny, G., van Adrichem, A., Mahé, C. & el Ghalbzouri, A. Different Gene Expression Patterns in Human Papillary and Reticular Fibroblasts. *Journal of Investigative Dermatology* **132**, 2565–2572 (2012).
20. Lee, D. Y. & Cho, K. H. The effects of epidermal keratinocytes and dermal fibroblasts on the formation of cutaneous basement membrane in three-dimensional culture systems. *Archives of Dermatological Research* **296**, 296–302 (2005).
21. Sorrell, J. M., Baber, M. A. & Caplan, A. I. Site-matched papillary and reticular human dermal fibroblasts differ in their release of specific growth factors/cytokines and in their interaction with keratinocytes. *Journal of Cellular Physiology* **200**, 134–145 (2004).
22. Dobie, R. *et al.* Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver Fibrosis. *Cell Reports* **29**, 1832–1847.e8 (2019).

23. Öhlund, D. *et al.* Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. *The Journal of experimental medicine* **214**, 579–596 (2017).
24. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. *Nature reviews. Cancer* **6**, 392–401 (2006).
25. Monteran, L. & Erez, N. The dark side of fibroblasts: Cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. *Frontiers in Immunology* vol. 10 1835 (2019).
26. Bartoschek, M. *et al.* Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. *Nature Communications* **9**, 5150 (2018).
27. Costa, A. *et al.* Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. *Cancer Cell* **33**, 463–479.e10 (2018).
28. Davidson, S. *et al.* Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth Correspondence In Brief. *CellReports* **31**, 107628 (2020).
29. Elyada, E. *et al.* Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. *Cancer Discovery* vol. 9 1102–1123 (2019).
30. Lambrechts, D. *et al.* Phenotype molding of stromal cells in the lung tumor microenvironment. *Nature Medicine* **24**, 1277–1289 (2018).
31. Patel, A. P. *et al.* Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. *Science* **344**, 1396–1401 (2014).
32. Puram, S. v *et al.* Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. *Cell* **171**, 1611–1624.e24 (2017).
33. Su, S. *et al.* CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. *Cell* **172**, 841–856.e16 (2018).
34. Brechbuhl, H. M. *et al.* Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. *Clinical Cancer Research* **23**, 1710–1721 (2017).
35. Kieffer, Y. *et al.* Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. *Cancer Discovery* **10**, 1330–1351 (2020).
36. Croft, A. P. *et al.* Distinct fibroblast subsets drive inflammation and damage in arthritis. *Nature* vol. 570 246–251 (2019).
37. Wei, K. *et al.* Notch signalling drives synovial fibroblast identity and arthritis pathology. *Nature* 1–6 (2020) doi:10.1038/s41586-020-2222-z.
38. Ospelt, C. Synovial fibroblasts in 2017. *RMD Open* vol. 3 (2017).
39. Zhang, F. *et al.* Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. *Nature Immunology* (2019) doi:10.1038/s41590-019-0378-1.

40. Biffi, G. *et al.* IL1-induced Jak/STAT signaling is antagonized by TGF β to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. *Cancer Discovery* **9**, 282–301 (2019).
41. Crowley, T. *et al.* Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts. *Arthritis Research & Therapy* **19**, 35 (2017).
42. Erez, N., Truitt, M., Olson, P. & Hanahan, D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF- κ B-Dependent Manner. *Cancer Cell* **17**, 135–147 (2010).
43. Koliarakis, V., Pasparakis, M. & Kollias, G. IKK β in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. *Journal of Experimental Medicine* **212**, 2235–2251 (2015).
44. Sohn, C. *et al.* Prolonged Tumor Necrosis Factor α Primes Fibroblast-like Synoviocytes in a Gene-Specific Manner by Altering Chromatin. *Arthritis & Rheumatology* **67**, 86–95 (2015).
45. Yang, X. *et al.* FAP Promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 Signaling. *Cancer Research* **76**, 4124–4135 (2016).
46. Jones, D. S. *et al.* Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. *Nature Chemical Biology* **13**, 38–45 (2017).
47. Koliarakis, V. *et al.* Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis. *Cell Reports* **26**, 536–545.e4 (2019).
48. Ospelt, C. *et al.* Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. *Arthritis and Rheumatism* **58**, 3684–3692 (2008).
49. Seki, E. *et al.* TLR4 enhances TGF- β signaling and hepatic fibrosis. *Nature Medicine* **13**, 1324–1332 (2007).
50. Zhao, S. *et al.* Selective deletion of MyD88 signaling in α -SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation. *Mucosal Immunology* (2020) doi:10.1038/s41385-020-0259-9.
51. Armaka, M. *et al.* Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. *Journal of Experimental Medicine* **205**, 331–337 (2008).
52. Nguyen, H. N. *et al.* Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. *Immunity* **46**, 220–232 (2017).
53. Aschenbrenner, D. *et al.* Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance. *Gut* **0**, 1–14 (2020).

54. le Goff, B. *et al.* Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts. *Cytokine* **68**, 101–109 (2014).
55. West, N. R. *et al.* Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. *Nature Medicine* **23**, 579–589 (2017).
56. Calvo, F. *et al.* Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. *Nat Cell Biol* **15**, 637–646 (2013).
57. Vaughan, M. B., Howard, E. W. & Tomasek, J. J. Transforming growth factor- β 1 promotes the morphological and functional differentiation of the myofibroblast. *Experimental Cell Research* **257**, 180–189 (2000).
58. Ramachandran, P. *et al.* *Resolving the fibrotic niche of human liver cirrhosis at single-cell level.* *Nature* vol. 575 (Springer US, 2019).
59. Wohlfahrt, T. *et al.* PU.1 controls fibroblast polarization and tissue fibrosis. *Nature* **566**, 344–349 (2019).
60. Parsonage, G. *et al.* A stromal address code defined by fibroblasts. (2004) doi:10.1016/j.it.2004.11.014.
61. Junt, T., Scandella, E. & Ludewig, B. Form follows function: Lymphoid tissue microarchitecture in antimicrobial immune defence. *Nature Reviews Immunology* vol. 8 764–775 (2008).
62. Tikhonova, A. N. *et al.* The bone marrow microenvironment at single-cell resolution. *Nature* **569**, 222–228 (2019).
63. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B. il & Nagasawa, T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. *Immunity* **20**, 707–718 (2004).
64. Krishnamurty, A. T. & Turley, S. J. Lymph node stromal cells: cartographers of the immune system. *Nature Immunology* **21**, 369–380 (2020).
65. Cheng, H. W. *et al.* Origin and differentiation trajectories of fibroblastic reticular cells in the splenic white pulp. *Nature Communications* **10**, 1–14 (2019).
66. Perez-Shibayama, C. *et al.* Type I interferon signaling in fibroblastic reticular cells prevents exhaustive activation of antiviral CD8+ T cells. *Science Immunology* **5**, (2020).
67. Pikor, N. B. *et al.* Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation. *Immunity* **43**, 1160–1173 (2015).
68. Rodda, L. B. *et al.* Single-Cell RNA Sequencing of Lymph Node Stromal Cells Reveals Niche-Associated Heterogeneity. *Immunity* **48**, 1014–1028.e6 (2018).

69. Link, A. *et al.* Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. *Nature immunology* **8**, 1255–1265 (2007).
70. Luther, S. A. *et al.* Differing Activities of Homeostatic Chemokines CCL19, CCL21, and CXCL12 in Lymphocyte and Dendritic Cell Recruitment and Lymphoid Neogenesis. *The Journal of Immunology* **169**, 424–433 (2002).
71. Luther, S. A., Tang, H. L., Hyman, P. L., Farr, A. G. & Cyster, J. G. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. *Proceedings of the National Academy of Sciences of the United States of America* **97**, 12694–12699 (2000).
72. Bajénoff, M. *et al.* Stromal Cell Networks Regulate Lymphocyte Entry, Migration, and Territoriality in Lymph Nodes. *Immunity* **25**, 989–1001 (2006).
73. Wang, X. *et al.* Follicular dendritic cells help establish follicle identity and promote B cell retention in germinal centers. *Journal of Experimental Medicine* **208**, 2497–2510 (2011).
74. Jarjour, M. *et al.* Fate mapping reveals origin and dynamics of lymph node follicular dendritic cells. *Journal of Experimental Medicine* **211**, 1109–1122 (2014).
75. Wu, Y. *et al.* IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. *International Immunology* **21**, 745–756 (2009).
76. Knoblich, K. *et al.* The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. *PLOS Biology* **16**, e2005046 (2018).
77. Fletcher, A. L. *et al.* Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. *Journal of Experimental Medicine* **207**, 689–697 (2010).
78. Lee, J. W. *et al.* Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. *Nature Immunology* **8**, 181–190 (2007).
79. Pikor, N. B. *et al.* Remodeling of light and dark zone follicular dendritic cells governs germinal center responses. *Nature Immunology* **21**, 649–659 (2020).
80. Gregory, J. L. *et al.* Infection Programs Sustained Lymphoid Stromal Cell Responses and Shapes Lymph Node Remodeling upon Secondary Challenge. *Cell Reports* **18**, 406–418 (2017).
81. Majumder, S. *et al.* IL-17 metabolically reprograms activated fibroblastic reticular cells for proliferation and survival. *Nature Immunology* **20**, 534–545 (2019).
82. Tan, K. W. *et al.* Expansion of Cortical and Medullary Sinuses Restrains Lymph Node Hypertrophy during Prolonged Inflammation. *The Journal of Immunology* **188**, 4065–4080 (2012).
83. Roulis, M. *et al.* Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. *Nature* **580**, 524–529 (2020).

84. Koliarakis, V., Henriques, A., Prados, A. & Kollias, G. Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. *Journal of Experimental Medicine* vol. 217 (2020).
85. Jacob, N. *et al.* Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. *Mucosal Immunology* **11**, 1466–1476 (2018).
86. Flannigan, K. L., Nieves, K., Alston, L., Mani, S. & Hirota, S. A. Sensing of a microbial metabolite by fibroblasts through the pregnane X receptor restrains inflammation and fibrosis in mice. *Journal of the Canadian Association of Gastroenterology* **2**, 30–31 (2019).
87. Martin, J. C. *et al.* Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell* **178**, 1493–1508.e20 (2019).
88. Dennis Jr, G. *et al.* Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. <http://arthritis-research.com/content/16/2/R90> (2011) doi:10.1186/2046-1682-4-13.
89. Lewis, M. J. *et al.* Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. *Cell Reports* **28**, 2455–2470.e5 (2019).
90. Buckley, C. D. *et al.* Persistent Induction of the Chemokine Receptor CXCR4 by TGF- β 1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium. *The Journal of Immunology* **165**, 3423–3429 (2000).
91. Bunney, P. E., Zink, A. N., Holm, A. A., Billington, C. J. & Kotz, C. M. Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. *Physiology & Behavior* **176**, 139–148 (2017).
92. Firestein, G. S., Alvaro-Gracia, J. M., Maki, R. & Alvaro-Garcia, J. M. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. *The Journal of Immunology* **144**, (1990).
93. Pilling, D. *et al.* Interferon- β mediates stromal cell rescue of T cells from apoptosis. *European Journal of Immunology* **29**, 1041–1050 (1999).
94. Tran, C. N. *et al.* Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes Role of Membrane Tumor Necrosis Factor-on Cytokine-Activated T Cells. *Am J Pathol* **171**, 1588–1598 (2007).
95. Müller-Ladner, U. *et al.* Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. *American Journal of Pathology* **149**, 1607–1615 (1996).
96. Crowley, T., Buckley, C. D. & Clark, A. R. Stroma: the forgotten cells of innate immune memory. *Clinical and Experimental Immunology* **193**, 24–36 (2018).

97. Ai, R. *et al.* DNA methylome signature in synoviocytes from patients with early rheumatoid arthritis compared to synoviocytes from patients with longstanding rheumatoid arthritis. *Arthritis and Rheumatology* **67**, 1978–1980 (2015).
98. Firestein, G. S. DNA methylome signature in rheumatoid arthritis. *Japanese Journal of Clinical Immunology* **35**, 367b–367b (2012).
99. Karouzakis, E. *et al.* Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis. *Scientific Reports* **8**, 7370 (2018).
100. Whitaker, J. W. *et al.* An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype. *Genome Medicine* **5**, (2013).
101. Barone, F. *et al.* Stromal fibroblasts in tertiary lymphoid structures: A novel target in chronic inflammation. *Frontiers in Immunology* **7**, 1–19 (2016).
102. Buckley, C. D., Barone, F., Nayar, S., Bénézech, C. & Caamaño, J. Stromal cells in chronic inflammation and tertiary lymphoid organ formation. *Annual Review of Immunology* **33**, 715–745 (2015).
103. Cañete, J. D. *et al.* Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. (2011) doi:10.1186/s13075-015-0688-0.
104. Goya, S. *et al.* Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. *Journal of Pathology* **200**, 82–87 (2003).
105. Husson, H. *et al.* Functional effects of TNF and lymphotoxin $\alpha 1\beta 2$ on FDC-like cells. *Cellular Immunology* **203**, 134–143 (2000).
106. Lee, J. J. *et al.* Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. *Pneumologie* **52**, 168 (1998).
107. Luther, S. A., Ansel, K. M. & Cyster, J. G. Overlapping roles of CXCL13, interleukin 7 receptor α , and CCR7 ligands in lymph node development. *Journal of Experimental Medicine* **197**, 1191–1198 (2003).
108. Nayar, S. *et al.* Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. *Proceedings of the National Academy of Sciences of the United States of America* **116**, 13490–13497 (2019).
109. Barone, F. *et al.* IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. *Proceedings of the National Academy of Sciences of the United States of America* **112**, 11024–11029 (2015).
110. Peduto, L. *et al.* Inflammation Recapitulates the Ontogeny of Lymphoid Stromal Cells. *The Journal of Immunology* **182**, 5789–5799 (2009).
111. Luther, S. A., Lopez, T., Bai, W., Hanahan, D. & Cyster, J. G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. *Immunity* **12**, 471–481 (2000).

112. Rangel-Moreno, J. *et al.* The development of inducible bronchus-associated lymphoid tissue depends on IL-17. *Nature Immunology* **12**, 639–646 (2011).
113. Wu, Q. *et al.* Reversal of spontaneous autoimmune insulinitis in nonobese diabetic mice by soluble lymphotoxin receptor. *Journal of Experimental Medicine* **193**, 1327–1332 (2001).
114. Link, A. *et al.* Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. *American Journal of Pathology* **178**, 1662–1675 (2011).
115. Manzo, A. *et al.* CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis. *American Journal of Pathology* **171**, 1549–1562 (2007).
116. Bugatti, S. *et al.* High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. *Rheumatology (United Kingdom)* **53**, 1886–1895 (2014).
117. Cantaert, T. *et al.* B Lymphocyte Autoimmunity in Rheumatoid Synovitis Is Independent of Ectopic Lymphoid Neogenesis. *The Journal of Immunology* **181**, 785–794 (2008).
118. Klimiuk, P. A., Goronzy, J. J., Björnsson, J., Beckenbaugh, R. D. & Weyand, C. M. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. *American Journal of Pathology* **151**, 1311–1319 (1997).
119. Lanfant-Weybel, K. *et al.* Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy - A pilot study from the VERA cohort. *Joint Bone Spine* **79**, 574–580 (2012).
120. Thurlings, R. M. *et al.* Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. *Arthritis and Rheumatism* **58**, 1582–1589 (2008).
121. van de Sande, M. G. H. *et al.* Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: Is it a constant feature over time? *Annals of the Rheumatic Diseases* **70**, 700–703 (2011).
122. Risselada, A. P., Looije, M. F., Kruize, A. A., Bijlsma, J. W. J. & van Roon, J. A. G. The Role of Ectopic Germinal Centers in the Immunopathology of Primary Sjögren's Syndrome: A Systematic Review. *Seminars in Arthritis and Rheumatism* **42**, 368–376 (2013).
123. Theander, E. *et al.* Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. *Annals of the Rheumatic Diseases* **70**, 1363–1368 (2011).
124. Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. *Nature Reviews Cancer* vol. 19 307–325 (2019).
125. Cabrita, R. *et al.* Tertiary lymphoid structures improve immunotherapy and survival in melanoma. *Nature* **577**, 561–565 (2020).

126. Vinay, D. S. *et al.* Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Seminars in Cancer Biology* **35**, S185–S198 (2015).
127. Hanson, H. L. *et al.* Eradication of established tumors by CD8+ T cell adoptive immunotherapy. *Immunity* **13**, 265–276 (2000).
128. Matsushita, H. *et al.* Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. *Nature* **482**, 400–404 (2012).
129. Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. *Genes and Development* vol. 32 1267–1284 (2018).
130. Borghaei, H. *et al.* Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *New England Journal of Medicine* **373**, 1627–1639 (2015).
131. Hamid, O. *et al.* Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Annals of Oncology* **30**, 582–588 (2019).
132. Motzer, R. J. *et al.* Nivolumab versus everolimus in advanced renal-cell carcinoma. *New England Journal of Medicine* **373**, 1803–1813 (2015).
133. Seiwert, T. Y. *et al.* Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *The Lancet Oncology* **17**, 956–965 (2016).
134. Dieu-Nosjean, M. C. *et al.* Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. *Journal of Clinical Oncology* **26**, 4410–4417 (2008).
135. Ladányi, A. *et al.* Density of DC-LAMP + mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. *Cancer Immunology, Immunotherapy* **56**, 1459–1469 (2007).
136. Martinet, L. *et al.* Human solid tumors contain high endothelial venules: Association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. *Cancer Research* **71**, 5678–5687 (2011).
137. Goc, J. *et al.* Dendritic cells in tumor-associated tertiary lymphoid structures signal a th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ t cells. *Cancer Research* **74**, 705–715 (2014).
138. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. *Nature* vol. 480 480–489 (2011).
139. Montfort, A. *et al.* A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. *Clinical Cancer Research* **23**, 250–262 (2017).
140. Germain, C. *et al.* Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. *American Journal of Respiratory and Critical Care Medicine* **189**, 832–844 (2014).

141. Nielsen, J. S. *et al.* CD20+ tumor-infiltrating lymphocytes have an atypical CD27 - memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. *Clinical Cancer Research* **18**, 3281–3292 (2012).
142. Schlößer, H. A. *et al.* B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. *OncolImmunology* **8**, (2019).
143. Chen, L., Qiu, X., Wang, X. & He, J. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. *Biochemical and Biophysical Research Communications* **487**, 8–14 (2017).
144. Cohen, N. *et al.* Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. *Oncogene* **36**, 4457–4468 (2017).
145. Comito, G. *et al.* Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. *Oncogene* **33**, 2423–2431 (2014).
146. Gunderson, A. J. *et al.* Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. *PLOS ONE* **14**, e0211117 (2019).
147. Ksiazkiewicz, M. *et al.* Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. *Immunobiology* **215**, 737–747 (2010).
148. Pautu, J. L. & Kumar, L. Intratumoral T cells and survival in epithelial ovarian cancer. *The National medical journal of India* **16**, 150–151 (2003).
149. Azimi, F. *et al.* Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *Journal of Clinical Oncology* **30**, 2678–2683 (2012).
150. Galon, J. *et al.* Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* **313**, 1960–1964 (2006).
151. Feig, C. *et al.* Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America* **110**, 20212–20217 (2013).
152. Gorchs, L. *et al.* Human pancreatic carcinoma-associated fibroblasts promote expression of co-inhibitory markers on CD4+ and CD8+ T-cells. *Frontiers in Immunology* **10**, 847 (2019).
153. Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P. & Shields, J. D. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. *Nature Communications* **9**, 948 (2018).

154. Hsu, Y. L. *et al.* Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. *Oncotarget* **7**, 27584–27598 (2016).
155. Xiao, Q. *et al.* Cancer-associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation. *Cancer Research* **76**, 5395–5404 (2016).
156. Vizoso, M. *et al.* Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. *Carcinogenesis* **36**, 1453–1463 (2015).
157. Albregues, J. *et al.* Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. *Nature Communications* **6**, (2015).
158. Direkze, N. C. *et al.* Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. *Cancer Research* **64**, 8492–8495 (2004).
159. Hosaka, K. *et al.* Pericyte-fibroblast transition promotes tumor growth and metastasis. *Proceedings of the National Academy of Sciences of the United States of America* **113**, E5618–E5627 (2016).
160. Ishii, G. *et al.* In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. *Stem cells (Dayton, Ohio)* **23**, 699–706 (2005).
161. Petersen, O. W. *et al.* Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. *The American journal of pathology* **162**, 391–402 (2003).
162. Quante, M. *et al.* bone marrow-derived myofibroblasts contribute to the growth MSC niche and promote tumour growth. *Cancer Cell* **19**, 257–272 (2012).
163. Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. *Cancer Research* **67**, 10123–10128 (2007).
164. Raz, Y. *et al.* Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. *Journal of Experimental Medicine* **215**, 3075–3093 (2018).
165. Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell–cell communication from combined expression of multi-subunit ligand–receptor complexes. *Nature Protocols* **15**, 1484–1506 (2020).
166. Browaeys, R., Saelens, W. & Saeys, Y. NicheNet: modeling intercellular communication by linking ligands to target genes. *Nature Methods* **17**, 159–162 (2020).
167. Duperret, E. K. *et al.* Alteration of the tumor stroma using a consensus DNA vaccine targeting Fibroblast Activation Protein (FAP) synergizes with antitumor vaccine therapy in Mice. *Clinical Cancer Research* **24**, 1190–1201 (2018).
168. Fang, J. *et al.* A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice. *International Journal of Cancer* **138**, 1013–1023 (2016).

169. Loeffler, M., Krüger, J. A., Niethammer, A. G. & Reisfeld, R. A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. *Journal of Clinical Investigation* **116**, 1955–1962 (2006).
170. Ostermann, E. *et al.* Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. *Clinical Cancer Research* **14**, 4584–4592 (2008).
171. Wang, L. C. S. *et al.* Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer immunology research* **2**, 154–166 (2014).
172. Roberts, E. W. *et al.* Depletion of stromal cells expressing fibroblast activation protein- α from skeletal muscle and bone marrow results in cachexia and anemia. *Journal of Experimental Medicine* **210**, 1137–1151 (2013).
173. Özdemir, B. C. *et al.* Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. *Cancer cell* **25**, 719–734 (2014).
174. Calon, A. *et al.* Dependency of Colorectal Cancer on a TGF- β -Driven Program in Stromal Cells for Metastasis Initiation. *Cancer Cell* **22**, 571–584 (2012).
175. Mariathasan, S. *et al.* TGF β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* **554**, 544–548 (2018).
176. Ohshio, Y. *et al.* Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine. *Cancer Science* **106**, 134–142 (2015).
177. Takai, K., Le, A., Weaver, V. M. & Werb, Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. *Oncotarget* **7**, 82889–82901 (2016).
178. Bai, Y. P. *et al.* FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. *Cancer Science* **106**, 1278–1287 (2015).
179. Sherman, M. H. *et al.* Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. *Cell* **159**, 80–93 (2014).
180. Katoh, M. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). *International Journal of Molecular Medicine* vol. 38 3–15 (2016).
181. Richeldi, L. *et al.* Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine* **370**, 2071–2082 (2014).
182. Tan, H.-Y. *et al.* Targeting tumour microenvironment by tyrosine kinase inhibitor. *Molecular Cancer* **17**, (2018).
183. Alivernini, S. *et al.* Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. *Nature Medicine* (2020) doi:10.1038/s41591-020-0939-8.

184. Atreya, R. *et al.* Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo. *Nature Medicine* **6**, 583–588 (2000).
185. Danese, S. *et al.* Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). *Gut* **68**, 40–48 (2019).
186. Gout, T., Östör, A. J. K. & Nisar, M. K. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: A systematic literature review. *Clinical Rheumatology* **30**, 1471–1474 (2011).
187. Duerr, R. H. *et al.* A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* **314**, 1461–1463 (2006).
188. Elson, C. O. *et al.* Monoclonal Anti-Interleukin 23 Reverses Active Colitis in a T Cell-Mediated Model in Mice. *Gastroenterology* **132**, 2359–2370 (2007).
189. Yen, D. *et al.* IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *Journal of Clinical Investigation* **116**, 1310–1316 (2006).
190. Hueber, W. *et al.* Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo- controlled trial. *Gut* **61**, 1693–1700 (2012).
191. Targan, S. R. *et al.* A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. *American Journal of Gastroenterology* **111**, 1599–1607 (2016).
192. Al-Sadi, R. *et al.* Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway. *PLoS ONE* **9**, (2014).
193. Lee, J. S. *et al.* Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. *Immunity* **43**, 727–738 (2015).
194. Mueller, L. *et al.* Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. *American Journal of Pathology* **171**, 1608–1618 (2007).
195. Meng, F. *et al.* Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. *Gastroenterology* **143**, 765–776.e3 (2012).
196. Park, M. J. *et al.* IL-1-IL-17 signaling axis contributes to fibrosis and inflammation in two different murine models of systemic sclerosis. *Frontiers in Immunology* **9**, 1611 (2018).
197. Sun, B. *et al.* Role of interleukin 17 in TGF- β signaling-mediated renal interstitial fibrosis. *Cytokine* **106**, 80–88 (2018).
198. Khalili, J. S. *et al.* Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. *Clinical Cancer Research* **18**, 5329–5340 (2012).

199. Kook, S. H., Jang, Y. S. & Lee, J. C. Human periodontal ligament fibroblasts stimulate osteoclastogenesis in response to compression force through TNF- α -mediated activation of CD4+ T cells. *Journal of Cellular Biochemistry* **112**, 2891–2901 (2011).
200. Wong, V. W. *et al.* Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. *Nature Medicine* (2011) doi:10.1038/nm.2574.
201. Li, Z. *et al.* Transforming growth factor- β and substrate stiffness regulate portal fibroblast activation in culture. *Hepatology* **46**, 1246–1256 (2007).
202. Niu, L. *et al.* Matrix stiffness controls cardiac fibroblast activation through regulating YAP via AT1R. *Journal of Cellular Physiology* **235**, 8345–8357 (2020).
203. Zhao, X. H. *et al.* Force activates smooth muscle α -actin promoter activity through the Rho signaling pathway. *Journal of Cell Science* **120**, 1801–1809 (2007).
204. Calvo, F. *et al.* Cdc42EP3/BORG2 and Septin Network Enables Mechano-transduction and the Emergence of Cancer-Associated Fibroblasts. *Cell Reports* **13**, 2699–2714 (2015).
205. Georganas, C. *et al.* Regulation of IL-6 and IL-8 Expression in Rheumatoid Arthritis Synovial Fibroblasts: the Dominant Role for NF- κ B But Not C/EBP β or c-Jun. *The Journal of Immunology* **165**, 7199–7206 (2000).
206. Tran, C. N. *et al.* Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. *Arthritis and Rheumatism* **56**, 1497–1506 (2007).
207. Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. *Immunological Reviews* **233**, 233–255 (2010).
208. Kumar, V. *et al.* Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. *Cancer Cell* **32**, 654–668.e5 (2017).
209. Deng, Y. *et al.* Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells. *Nature Publishing Group* **36**, 1090–1101 (2017).
210. D'Amico, L. *et al.* Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. *Journal of Experimental Medicine* **213**, 827–840 (2016).
211. Mace, T. A. *et al.* Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a StAT3-dependent manner. *Cancer Research* **73**, 3007–3018 (2013).
212. Cheng, J. *et al.* Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. *Oncogenesis* **5**, e198–e198 (2016).

213. de Monte, L. *et al.* Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. *The Journal of experimental medicine* **208**, 469–478 (2011).
214. Ruhland, M. K. *et al.* Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. *Nature Communications* **7**, 11762 (2016).
215. Westendorp, B. F. *et al.* Indian Hedgehog Suppresses a Stromal Cell–Driven Intestinal Immune Response. *CMGH* **5**, 67-82.e1 (2018).
216. Tauriello, D. V. F. *et al.* TGF β drives immune evasion in genetically reconstituted colon cancer metastasis. *Nature* **554**, 538–543 (2018).
217. Givel, A. M. *et al.* MiR200-regulated CXCL12 β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. *Nature Communications* **9**, 1056 (2018).
218. Filer, A. *et al.* Identification of a transitional fibroblast function in very early rheumatoid arthritis. *Annals of the rheumatic diseases* **76**, 2105–2112 (2017).
219. Burger, J. A., Zvaifler, N. J., Tsukada, N., Firestein, G. S. & Kipps, T. J. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. *Journal of Clinical Investigation* **107**, 305–315 (2001).
220. Reparon-Schuijt, C. C. *et al.* Regulation of synovial B cell survival nrheumatoid arthritis by vascular cell adhesion molecule 1 (CD106) expressed on fibroblast-like synoviocytes. *Arthritis and Rheumatism* **43**, 1115–1121 (2000).
221. Pilling, D. *et al.* Interferon- I mediates stromal cell rescue of T cells from apoptosis. 1041–1050 (1999).
222. Barnas, J. L., Simpson-Abelson, M. R., Brooks, S. P., Kelleher, R. J. & Bankert, R. B. Reciprocal Functional Modulation of the Activation of T Lymphocytes and Fibroblasts Derived from Human Solid Tumors. *The Journal of Immunology* **185**, 2681–2692 (2010).
223. Ivanov, I. I. *et al.* The Orphan Nuclear Receptor ROR γ t Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells. *Cell* **126**, 1121–1133 (2006).

Figures and tables

Figure 1: Fibroblast heterogeneity in health and disease across tissue

Fibroblast heterogeneity in homeostasis and disease in the gut (A), synovium (B), and lung (C). (A) Fibroblasts are shaped by their position in the crypt axis, with subsets expressing SOX6 and POSTN positioned in close proximity to the epithelium to facilitate epithelial regeneration. In the context of inflammation, the emergence of a THY1+PDPN+FAP+ subset is seen close to the site of mucosal barrier breakdown, orchestrating recruitment of

leucocytes via release of cytokines and appropriate chemokines. (B) The synovium in health and RA. Lining layer fibroblasts produce lubricin to lubricate healthy joints. However, in RA, this population acquires a remodelling phenotype, producing MMPs to break down cartilage and activating osteoclasts to erode bone. iii. In this disease state, the sublining expands and a THY1+ PDPN+ FAP+ population emerges surrounding the blood vessels. Similar to the gut, this population produces inflammatory cytokines. (C) Fibroblast heterogeneity in the healthy and fibrotic lung. AXIN2+ PDGFRA+ fibroblasts reside close to the alveolar niche, where they support stem cell maintenance. A distinct AXIN2+ PDGFRA- population resides closer to the airways. This population acquires a pathogenic remodelling phenotype in disease, promoting fibrosis.

Figure 2: Common mechanisms regulating proinflammatory and remodelling populations across disease.

Two pathogenic fibroblast populations are commonly found across disease: inflammatory and tissue remodelling. These populations are regulated by similar signalling pathways. (A). Inflammatory factors derived from immune infiltrates activate an inflammatory profile in fibroblasts via NFkB. (B) NFkB induces production of LIF, which activates JAK/STAT signalling, propagating NFkB signalling, inducing a positive feedback loop. (C) Inflammatory factors produced by fibroblasts recruit more immune cells, further exacerbating this process. (D) Stromal signals induce expansion of both inflammatory and remodelling populations, including JAG1 and DLL4 activation of Notch3 Notch ligands on endothelium. (E) Physical cues, including matrix stiffening, combine with soluble stimuli to promote the remodelling phenotype. In cancer these phenotypes are interchangeable, depending on the cues that are exposed to.

Figure 3: Transformation of fibroblast functions in inflammation

(A) Environmental insults activate pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) on mononuclear phagocytes and granulocytes, in keeping with an acute inflammatory response. (B) Subsequent release of cytokines such as TNF-alpha or oncostatin M (OSM) from these cells induce a pro-inflammatory phenotype in fibroblasts, that is shaped by local tissue ecosystems. (C) In the setting of chronic inflammation, the local cytokine milieu primes LTo-like stromal cells. This induces expression of chemokines such as CCL19, CCL21 as well CXCL12 and CXCL13. (D) Over time, this LTo-like stromal cell recruits naïve CD4+ cells, DAMP3+ DCs, and follicular B cells to its location, eventually giving rise to a tertiary lymphoid structure.

Figure 4: Fibroblast immune modulation in cancer

Cancer associated fibroblasts (CAFs) have both pro-inflammatory and immunosuppressive properties in the tumour microenvironment. (A) CAFs recruit myeloid cells to the TME by producing cytokines such as CCL2, CCL5, CXCL8, CXCL12, Chi3L1 and IL6. The presence of T-

cells is associated with immune mediated tumour destruction. As such tumours cultivate an immunosuppressive environment in which, T-cells are actively excluded or held in a dysfunctional state, characterised by expression of exhaustion markers PD1, Lag3 and Tim3 (B). CAFs contribute to T-cell dysfunction by antigen-dependent deletion (C), in which CAFs present antigen via MHCI, while engaging Tcell receptors PD1 and FAS, with PDL2 and FasL. CAFs also actively exclude T-cells from the tumour by producing TGFβ and CXCL12 (D). Finally, CAFs contribute to the tumour immunosuppressive environment by polarising macrophages towards a suppressive phenotype (mediated by CXCL12 and Chi3L1), inducing Myeloid derived suppressor cells (MDSCs, via CXCL12, DKK1 and Il6), as well as reducing ability of dendritic cells to present antigen and activate adaptive immunity (via TDO2/kynurenine, TLSP, IL6).

Figure 5: Harnessing fibroblasts for therapeutics

To therapeutically target fibroblasts in disease, 3 main approaches can be taken. Current therapies have mostly focussed on targeting and deleting FAP+ fibroblasts, using CAR T-cells, DNA vaccines and anti-FAP antibodies (A). An alternate approach is to directly target fibroblast effector functions, such as blocking the action of inflammatory or immunosuppressive factors (B). Finally, to switch fibroblasts from a pro-inflammatory to an immunosuppressive state, or vice versa, inductive programs can be induced or disrupted. Possible target programs are highlighted in (C).

Tables

Table 1. Common mechanisms of fibroblast activation across tissue and disease

Table displays mechanisms that activate pathogenic properties in fibroblast in disease. Disease type and tissue of origin are indicated.

Mechanism of Activation	Disease	Organ	References
TLRs			
TLR2	Rheumatoid Arthritis	Joints	⁴
TLR3	Rheumatoid Arthritis	Joints	^{5,6,46}

TLR4	Liver fibrosis Rheumatoid Arthritis Intestinal Cancer	Liver Joints Gut	49 48 47
TLR5	Intestinal Fibrosis (UC/Crohn's)	Gut	50
Cytokines			
TNF	Rheumatoid Arthritis Inflammatory Bowel Disease Cancer	Joints Gut Colorectal liver metastasis	46,51 51 194
OSM	Inflammatory Bowel Disease	Gut	55
IL17	Fibrosis	Liver Skin Gut	195 196 197
IL1B	Cancer	Skin Pancreas	42,198 42
Il1a	Cancer Rheumatoid arthritis	Pancreas Skin Joints	40 198 46
Mechanical Force	- Wound healing Cancer	Periodontium Skin Liver Heart Breast	199 200 201 202,203 56,204
Signaling Pathways			

NFkB	Cancer	Gut	43
		Skin	20,42
		Pancreas	40,42
	Rheumatoid Arthritis	Joints	41,44,205
STAT3	Cancer	Pancreas	40
		Liver	45
STAT4	Rheumatoid Arthritis	Joints	52
STAT1	Rheumatoid Arthritis	Joints	44

Table 2. Common mechanisms of immune regulation

Table displays common mechanisms through which fibroblasts regulate immune recruitment, activation and suppression, in disease. Disease and anatomical site are indicated.

Mechanism of Immune Regulation	Disease	Organ	References
Antigen presentation			
MHCI	Cancer	Skin	153
MHCII	Inflammation: RA	Joints	91,206
	Cancer	Pancreas	29
Attraction of Myeloid Cells			
CCL2	Inflammation: RA	Joints	207
	Inflammation: IBD	Gut	87
	Cancer	Breast	147
		Liver	45

		Colon	143
CCL5	Inflammation: RA	Joints	207
CCL8	Inflammation: RA	Joints	207
CXCL1	Inflammation: IBD Cancer	Gut Colon Lung Breast Skin Pancreas	87 208 208 208 208 146
CXCL2	Inflammation: IBD	Gut	13
CXCL5	Inflammation: RA	Joints	207
CXCL8	Inflammation IBD	Gut	13
CXCL10	Inflammation: RA	Joints	207
CXCL12	Cancer	Prostate	145
Chi3L1	Cancer	Breast	144
Il6	Cancer	pancreatic	23
Immunosuppression			
CXCL12 (Macrophages, MDSC)	Cancer	Prostate Liver	145 209
DKK1 (MDSC)	Cancer	Skin Lung	210 210
Il6 (MDSCs, DCs)	Cancer	Pancreas Liver	211 212
TDO2/Kynurenine (DCs)	Cancer	Lung	154
TLSP (DCs)	Cancer	Pancreas	213

FASL (T-cells)	Cancer	Skin	153
PDL1 (T-cells)	Cancer	Skin Pancreas	198 152
PDL2 (T-cells)	Cancer	Skin Pancreas	153,198 152
PGE2 (T-cells)	Cancer	Skin Pancreas	(Khalili et al., 2012)(Khalili et al., 2012) (Gorchs et al., 2019)(Gorchs et al., 2019)
Chi3L1 (Macrophages)	Cancer	Breast	144
SASP:CCL8, CXCL5, CCL2, CCL7, IL6, CXCL1, CXCL14, CCL5 (MDSC)	Cancer	Skin	214
T-cells Attraction/retention/ Exclusion			
CXCL12	Inflammation: IBD Cancer (Exclusion)	Gut Pancreas	215 151
TGFB	Cancer (Exclusion) Inflammation: RA (Attraction)	Bladder Colon Joints	175 216 90
OX40L	Cancer (retention of Tregs)	Breast Ovary	27 217
JAM2	Cancer (retention of Tregs)	Breast HGSOC	27 217
CCL19	Inflammation: IBD	Gut	17
CCL21	Inflammation: IBD	Gut	17

Endothelial Adhesion			
Upregulation VCAM	Inflammation: RA	Joints	²¹⁸
Upregulation ICAM	Inflammation: RA	Joints	²¹⁸
Survival Factors			
CXCL12	Inflammation: RA	Joints	²¹⁹
VCAM	Inflammation: RA	Joints	^{219,220}
BAFF	Inflammation: RA	Joints	⁵
APRIL	Inflammation: RA	Joints	⁵
Type1 interferons	Inflammation: RA	Joints	²²¹
Other			
Il6 (Th17 differentiation)	Cancer	Lung	²²²
	Inflammation: RA	Joints	²²³

Gut

Health

IBD

Inflammation

Chemokines
Cytokines

WNT5A
WNT5B

SOX6
POSTN
WNT2B

Epithelial
maintenance

WNT2B

ACTA2
myofibroblast

WNT2B+
RSPO3+

Joint lubrication Protective barrier

PRG4
CD55
CLIC5

Synovium

Health

RA

Damage
MMPs
Osteoclastogenesis

Inflammation
Chemokines
Cytokines

THY1
FAP
PDPN

Lung

Health

Fibrosis

AXIN2
PDGFR α

**Stem cell
maintenance**

Damage
Collagens
Matrix remodeling
enzymes

A

B

C


Immune-interacting fibroblasts:

Cancer, RA and IBD: Cytokines and chemokines

Tissue Remodeling fibroblasts:


Fibrosis & Cancer: Fibrotic ECM proteins, MMPs, cross-linking enzymes

RA: Cartilage destruction and promotion of osteoclastogenesis





Acute inflammation

Chronic inflammation



Inflammatory


Immunosuppressive



T-cells in the TME are dysfunctional and express exhaustion markers


A.

Cell based approach



B.

Effector approach



C.

Inductive program approach

